Exelixis Inc. Reports Q1 2025 Revenue Surge to $555.4M; Non-GAAP EPS Climbs to $0.62

Reuters
2025/05/14
Exelixis Inc. Reports Q1 2025 Revenue Surge to $555.4M; Non-GAAP EPS Climbs to $0.62

Exelixis Inc. has released its financial results for the first quarter of 2025, showcasing a notable increase in non-GAAP net income compared to the same period in 2024. The non-GAAP net income for the quarter ended March 31, 2025, was reported at $179.6 million, or $0.64 per share basic and $0.62 per share diluted. This reflects a significant rise from the non-GAAP net income of $52.0 million, or $0.17 per share basic and diluted, reported for the comparable period in 2024. Exelixis has also updated its financial guidance for fiscal year 2025. The company now anticipates total revenues to be in the range of $2.25 billion to $2.35 billion, an increase from the previous guidance of $2.15 billion to $2.25 billion. Similarly, net product revenues are expected to reach between $2.05 billion and $2.15 billion, up from the earlier forecasted range of $1.95 billion to $2.05 billion. These updates reflect Exelixis' ongoing efforts to enhance its financial performance and provide investors with useful supplementary information through the presentation of non-GAAP financial measures. The company continues to utilize these measures to better understand and evaluate its business operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exelixis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250513874586) on May 13, 2025, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10